Melvin Spigelman
Director/Board Member presso AN2 THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Melvin K.
Spigelman is currently the President, Chief Executive Officer & Director at Global Alliance for TB Drug Development.
He is also a Director at Tres Cantos Open Lab Foundation, a Director at AN2 Therapeutics, Inc., and a Venture Partner at Wellington Partners GmbH.
Previously, Dr. Spigelman served as the Chairman of Synergy Pharmaceuticals LLC from 2018 to 2019.
He was an Independent Director at The Medicines Co. from 2005 to 2018.
He also held the position of Vice President-Global Clinical Centers at Abbott India Ltd.
and Knoll Pharmaceutical Co. from 2000 to 2001.
Additionally, he was the President of Hudson-Douglas Ltd.
in 2003.
Dr. Spigelman received his undergraduate degree from Brown University and his doctorate from Icahn School of Medicine at Mount Sinai.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
AN2 THERAPEUTICS, INC.
-.--% | 07/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Melvin Spigelman
Società | Posizione | Inizio |
---|---|---|
AN2 THERAPEUTICS, INC. | Director/Board Member | 01/02/2022 |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Chief Executive Officer | 01/01/2009 |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Private Equity Investor | 01/01/2005 |
Tres Cantos Open Lab Foundation
Tres Cantos Open Lab Foundation Miscellaneous Commercial ServicesCommercial Services Tres Cantos Open Lab Foundation provides research facilities for charity. The non-profit company is based in Guildford, UK. | Director/Board Member | - |
Precedenti posizioni note di Melvin Spigelman
Società | Posizione | Fine |
---|---|---|
SYNERGY PHARMACEUTICALS INC | Chairman | 01/05/2019 |
THE MEDICINES COMPANY | Director/Board Member | 01/01/2018 |
Hudson-Douglas Ltd. | President | 01/06/2003 |
ABBOTT INDIA LIMITED | Chief Tech/Sci/R&D Officer | 01/01/2000 |
Knoll Pharmaceutical Co. | Chief Tech/Sci/R&D Officer | 01/01/2000 |
Formazione di Melvin Spigelman
Brown University | Undergraduate Degree |
Icahn School of Medicine at Mount Sinai | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
ABBOTT INDIA LIMITED | Health Technology |
AN2 THERAPEUTICS, INC. | Health Technology |
Aziende private | 7 |
---|---|
The Medicines Co.
The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Health Technology |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Finance |
Knoll Pharmaceutical Co. | |
Hudson-Douglas Ltd. | |
Tres Cantos Open Lab Foundation
Tres Cantos Open Lab Foundation Miscellaneous Commercial ServicesCommercial Services Tres Cantos Open Lab Foundation provides research facilities for charity. The non-profit company is based in Guildford, UK. | Commercial Services |
Synergy Pharmaceuticals LLC
Synergy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Synergy Pharmaceuticals LLC engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai and is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Melvin Spigelman